GWPH - GW Pharmaceuticals plc

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
+7.65 (+5.31%)
At close: 4:00PM EST

151.60 0.00 (0.00%)
After hours: 4:32PM EST

Stock chart is not supported by your current browser
Previous Close143.95
Bid144.00 x 800
Ask151.99 x 1300
Day's Range145.18 - 152.48
52 Week Range90.14 - 179.65
Avg. Volume479,461
Market Cap4.903B
Beta (3Y Monthly)3.61
PE Ratio (TTM)N/A
EPS (TTM)-10.61
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est172.15
Trade prices are not sourced from all markets
  • Benzinga7 hours ago

    Thailand Legalizes Medical Weed: What's Next?

    Thai King Maha Vajiralongkorn signed into law a bill legalizing medical use of cannabis earlier this week. In November, the Thai National Legislative Assembly submitted a number of amendments to the Health Ministry that would legalize marijuana and a local plant, kratom, for medical use.

  • Marijuana Stocks and ETFs: Risks and Rewards
    Zacks7 hours ago

    Marijuana Stocks and ETFs: Risks and Rewards

    Pot stocks are soaring again. To learn more about risks and rewards of investing in marijuana stocks and ETFs, check out this Exploring ETFs video.

  • ACCESSWIRE11 hours ago

    Four Marijuana Stocks Leading Friday's Bull Charge

    CORAL GABLES, FL / ACCESSWIRE / February 22, 2019 / The marijuana stock market has taken over media headlines over the course of the past few years, during the course of which top players in the cannabis industry have seen a substantial increase in investor interest. Considering the innovative approaches companies in the sector are taking to develop high-quality products for cannabis consumers, it makes perfect sense that this had resulted in the excitement surrounding the market. In addition to the positive shift in public opinion, lawmakers across the global cannabis space are putting forth legislation in favor of legalizing marijuana.

  • GW Pharmaceuticals PLC (GWPH) Dips More Than Broader Markets: What You Should Know

    GW Pharmaceuticals PLC (GWPH) Dips More Than Broader Markets: What You Should Know

    GW Pharmaceuticals PLC (GWPH) closed the most recent trading day at $143.95, moving -1.32% from the previous trading session.

  • What Investors Need to Know About Investing in Marijuana Stocks

    What Investors Need to Know About Investing in Marijuana Stocks

    Let's look at what investors need to know about the marijuana industry and how to invest in the future of pot.

  • ETFs and Stocks to Tap the Marijuana Boom

    ETFs and Stocks to Tap the Marijuana Boom

    First it was bitcoin that made investors go on a mad rush, and today, it's marijuana. Now that legalization is steadily gaining traction across the U.S., more investors than ever before are looking for ways to cash in.

  • Benzinga2 days ago

    New York City Bans CBD Edibles: What Now?

    New York City’s decision marked the highest-profile location to prohibit the sale of CBD-infused edibles. Numerous businesses have begun to feel the effects, including shops offering CBD infusions to products as well as companies focusing on CBD as their selling point. Infused coffee makers like Flower Power Coffee are also likely to be impacted.

  • The Zacks Analyst Blog Highlights: GW, Innovative, KushCo, Canopy and Constellation
    Zacks3 days ago

    The Zacks Analyst Blog Highlights: GW, Innovative, KushCo, Canopy and Constellation

    The Zacks Analyst Blog Highlights: GW, Innovative, KushCo, Canopy and Constellation

  • 4 Marijuana Stocks to Watch in 2019
    Zacks3 days ago

    4 Marijuana Stocks to Watch in 2019

    Marijuana stocks may not have had a stellar year in 2018. But, this year could easily bring better news as things continue to expand and more new marijuana markets open up.

  • Top Stock Picks for the Week of Feb 19, 2019
    Zacks3 days ago

    Top Stock Picks for the Week of Feb 19, 2019

    Tracey Ryniec and Kevin Cook take a look at two highly ranked pot stocks.

  • Why Marijuana ETFs are on a High in 2019
    Zacks8 days ago

    Why Marijuana ETFs are on a High in 2019

    After being beaten down in the final quarter of 2018, pot stocks staged a nice comeback at the start of this year on the renewed appeal for riskier assets. Here's why ETFs are riding high this year.

  • 3 Very Popular Marijuana Stocks You Couldn't Pay Me to Buy
    Motley Fool9 days ago

    3 Very Popular Marijuana Stocks You Couldn't Pay Me to Buy

    Three of the five largest pot stocks by market cap are more trouble than they're worth.

  • 4 Best Marijuana Stocks to Play the Green Rush
    Zacks9 days ago

    4 Best Marijuana Stocks to Play the Green Rush

    Whether its eating a gooey, chocolatey brownie or taking a few hits off a freshly rolled joint, it???s common knowledge that a lot of people like to get high. Many investors, however, have yet to "light up." What are the best marijuana stocks out there right now?

  • ACCESSWIRE9 days ago

    4 Marijuana Stocks Bubbling with Excitement on Wednesday (2/13/19)

    For the future of the industry to be secured, lawmakers need to press onward with passing this type of legislation, because, ultimately, this will allow companies in the sector to continue operating and developing novel products to distribute throughout the domestic cannabis market, rather than in a select few states. Nabis Holdings (INNPF) (NAB), Canopy Growth Corp (CGC) (WEED), GW Pharmaceuticals plc (GWPH), and CV Sciences Inc (CVSI) are four cannabis companies worth keeping on your radar. Nabis Holdings (INNPF) (NAB) is a Canadian investment company determined to make strategic investments in a multitude of high-quality cash flowing assets across an array of businesses in the cannabis sector, primarily in U.S. limited license states.

  • Should You Buy, Sell, Or Hold These 7 Medical Cannabis Stocks?
    InvestorPlace9 days ago

    Should You Buy, Sell, Or Hold These 7 Medical Cannabis Stocks?

    Cannabis stocks are having a blistering start to 2019. The sector appeared to have peaked in the fall of 2018. As many had warned, marijuana stocks turned sharply lower following Canada's legalization going into effect in a classic "sell the news" event. However, since then, the tide has turned. This year, pot stocks are back with the sector ETF posting a 50% move off the lows. * 9 U.S. Stocks That Are Coming to Life Again Not surprisingly, this enthusiasm has carried both recreational and medicinal cannabis stocks higher. For today, let's focus on the medicinal space. The recreational plays have been getting more attention lately with all the blockbuster partnerships. However, there are some interesting business stories developing in the medical cannabis stock space as well.InvestorPlace - Stock Market News, Stock Advice & Trading TipsSource: Shutterstock Aurora Cannabis (ACB)Aurora Cannabis (NYSE:ACB) is getting a ton of attention this week thanks to its recent earnings report. Aurora initially disappointed the market as its revenue numbers came in below expectations. This point raised some confusion. The company reported CAD $48 million in cannabis revenues, which was below expectations. Total revenues, which included a few other minor accounting items, hit CAD $54 million. That number beat analysts' outlooks.ACB stock initially dropped about 5% following earnings. Since then, it reversed course and traded higher. That makes sense; at the end of the day, it's the forward outlook that matters here, not a few million dollars of revenue this past quarter. On that note, the most solid bullish argument for ACB stock is that its patient base is surging. This quarter, it reported more than 73,000 active registered patients -- more than 200% growth from the same quarter last year.Of course, bears will point to the huge losses that Aurora is reporting. The company lost CAD $238 million, which blows the revenue figure of CAD $54 million out of the water. Some of these losses appear tied to ramping up operations. For the back half of the year, Aurora projects positive EBITDA, and much smaller net income losses. That, combined with relatively downbeat sentiment here, make ACB stock a buy within its sector. Do be careful though, Aurora needs to start posting much smaller losses as its customer base increases or investors will lose patience fairly quickly. GW Pharmaceuticals (GWPH)When it comes to medical cannabis stocks -- as opposed to the recreational lane -- GW Pharmaceuticals (NASDAQ:GWPH) is the king. GW Pharmaceuticals got involved with its epilepsy drug well before the flood of marijuana stocks hit the market last year.GW capitalized on its first-mover advantage by already securing FDA approval for its therapy while other cannabis stocks are still getting their operations up and going. The company has gotten widespread insurance coverage approval for its drug, Epidiolex. * The 7 Best Video Game Stocks to Power Up Your Portfolio! Earlier this year GW confirmed that the vast majority of both fee-for-service and managed- Medicaid providers will cover Epidiolex. Big private providers, such as Express Scripts (NASDAQ:ESRX) are on board as well. GW recently raised $300 million. That cash should give it plenty of runway to get Epidolex sales up and going while also funding its numerous other in-progress clinical trials. For a pureplay marijuana biotech stock, it's hard to top GWPH.Source: Shutterstock Cara Therapeutics (CARA)Cara Therapeutics (NASDAQ:CARA) is a bit more undercover as a cannabis stock. The company specializes in various therapeutic treatment alternatives that can serve as alternatives to opioids. As we've seen in recent months, opioids are a crisis in America. An estimated 30,000 people or so die from overdoses every year.This opens an opportunity for Cara, which I previously described. As it is, Cara has various drug therapies in development for pain management. Some of these involve cannabinoids, although its lead clinical candidate does not. In any case, with China increasingly in the news, CARA stock should shine as doctors look for alternatives to dangerous traditional opioids. CARA stock is up from $12 to $17 recently and could rise a lot farther once it picks up more backers from the medical marijuana stock community.Source: Shutterstock KushCo Holdings (KSHB)KushCo Holdings (OTCMKTS:KSHB) is arguably the clearest medical marijuana distribution play in the United States at this time. The company used to be called Kush Bottles, which shows the company's main product line. However, KushCo has branched out past just packaging to provide a variety of supplies for medicinal marijuana sales. By partnering with more than 5,000 pharmacies and dispensaries around the world, KushCo has established a powerful first-mover advantage in its field.That said, there are reasons for caution with KSHB stock. You might think that this is a cheap stock. It is trading for less than $6 and is not listed on a major stock exchange. Despite those factors, KushCo has a market cap of more than $500 million, as the company has issued many shares to fund its growth. * The 3 Best Chinese Stocks to Buy for a Long-Term Portfolio As appealing as the "picks and shovels" play on the marijuana industry sounds, KSHB stock comes with risks. That $500 million market cap is backed by just $50 million or so in current assets, putting a 10x valuation multiple on its property, inventory, cash, and so on. Also, you should take note of the company's gross margin. Its gross margin has plummeted from 35% to 13% in recent quarters, resulting in KushCo making increasingly large losses despite growing revenues. KushCo has an interesting business model and a strong advantage from its robust distribution partnerships. But it needs to start showing that the business can turn profits before the stock can find further upside.Source: Shutterstock Pyxus International (PYX)What happens when a struggling more-than-century old tobacco company turns itself into a marijuana play? The stock soars. Meet the company previously called Alliance One, now known as Pyxus International (NYSE:PYX). For the past two decades or so, Alliance One showed flat to declining revenues as its tobacco business declined. So, last summer, using the hemp workaround to avoid legal issues, Pyxus pivoted to the marijuana market and changed its name, and PYX stock flew.In fact, PYX stock soared from $13 at the start of 2018 to as high as $40, aided by favorable calls from the likes of Citron Research, among others. But the enthusiasm wouldn't last long. Once investors came to their senses, they saw that Pyxus remained heavily in debt and stuck to its legacy tobacco business which faces uncertain prospects going forward. There are a lot of cannabis stocks out there; there aren't many that have more than a billion in debt like Pyxus does.PYX stock soared more than 30% on Tuesday following its earnings report. The market clearly liked what it saw, starting with nearly 10% revenue growth. But the company continues to lose large amounts of money. It reported a GAAP EPS loss of 56 cents per share. It will need a far bigger turnaround to justify anything close to its current share price. The recent share price spike offers speculators an ideal opportunity to sell PYX stock.Source: Shutterstock GB Sciences (GBLX)GB Sciences (OTCMKTS:GBLX) is -- in one way similar -- to KushCo. Despite trading on the Pink Sheets and having a tiny share price, GBLX stock isn't necessarily undervalued. GBLX stock, in fact, sells for under a quarter but, due to a large share count, has a market cap of almost $60 million.I don't want to pick on GBLX stock in particular, as there are a bunch of medical cannabis stocks like GBLX. But it's worth noting one like this to see the pattern. You find a bunch of these, companies that are attached to whatever the current trend is popular but don't have many resources of their own. * Buy Medical Marijuana Stocks for Legal Pot's Next Leg Up In the case of GB Sciences, they had just $3 million in cash as of their last quarterly report. That's not a good sign, as the company has $2.1 million in current liabilities and more than $8 million in total obligations. That will make it hard for the company to achieve its goals in terms of studying Parkinson's and other serious diseases. Yes, GB will put out more press releases and garner more media attention, but without far more cash, the stock isn't going anywhere in the long run. GBLX stock plummeted from a high of 80 cents to just 14 cents last year. If you're already long, take advantage of the recent rebound to get out at 24 cents -- GBLX will likely go a lot lower in coming months.Source: Shutterstock Lexaria Bioscience (LXRP)Lexaria Bioscience (OTCMKTS:LXRP), like GB Science, is a penny stock on the Pink Sheets exchange. However, LXRP has a lot more credibility and gives us a good example of the contrast between an investable speculation and a risky gamble. Lexaria is a higher-quality medical cannabis stock because it has a strong backer: Altria (NYSE:MO).Altria famously lifted Cronos (NASDAQ:CRON) into the big leagues with its massive investment at $12/share. CRON stock went on to hit $25. Altria got a lot less attention with its recent investment in Lexaria, but it may end up having a similar effect. Earlier this year, Altria agreed to invest up to $12 million into Lexaria.Why did it do that? Lexaria has a novel patented technique for oral delivery of drugs. Obviously, this potentially has a huge market in the medicinal marijuana space. As it is, Altria has validated the technology by investing in it and seeking to commercialize it for nicotine. At $1.30 a share and a $100 million market cap, LXRP stock is still highly speculative. But unlike many medical cannabis stocks, Lexaria has promising technology and enough financial backing to potentially deliver strong results for its investors.At the time of this writing, Ian Bezek owned MO stock. You can reach him on Twitter at @irbezek. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The 7 Best Video Game Stocks to Power Up Your Portfolio! * 7 Forever Stocks to Buy for Long-Term Gains * 5 Self-Driving Car Stocks to Buy Compare Brokers The post Should You Buy, Sell, Or Hold These 7 Medical Cannabis Stocks? appeared first on InvestorPlace.

  • ACCESSWIRE10 days ago

    Biotech and Cannabis Stocks That Are Emerging

    HENDERSON, NV / ACCESSWIRE / February 13, 2019 / One you should research right away, BioRestorative Therapies, Inc. (BRTX) , a life sciences company focused on stem cell-based therapies, is developing ...

  • GW Pharmaceuticals PLC (GWPH) Stock Sinks As Market Gains: What You Should Know
    Zacks11 days ago

    GW Pharmaceuticals PLC (GWPH) Stock Sinks As Market Gains: What You Should Know

    GW Pharmaceuticals PLC (GWPH) closed the most recent trading day at $144.55, moving -1.51% from the previous trading session.

  • Green Growth Brands Ended in the Red Last Week
    Market Realist12 days ago

    Green Growth Brands Ended in the Red Last Week

    IIPR, GTBIF, and ITHUF Rose, GGBXF Fell Last Week(Continued from Prior Part)Green Growth BrandsGreen Growth Brands (GGBXF) had an eventful week. The stock witnessed a sharp fall during the week. Aphria (APHA) rejected the company’s hostile bid to

  • Why Marijuana Stock GW Pharmaceuticals Soared 46.6% in January
    Motley Fool12 days ago

    Why Marijuana Stock GW Pharmaceuticals Soared 46.6% in January

    Investors should get an update on sales of Epidiolex on Feb. 26 when the British biopharmaceutical reports earnings.

  • 3 Legal Marijuana States Are Banning CBD Edibles. Here's Why.
    Motley Fool12 days ago

    3 Legal Marijuana States Are Banning CBD Edibles. Here's Why.

    New York, Maine, and Ohio are waging war on CBD-infused food and beverages.

  • Benzinga14 days ago

    Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week

    This was not the best of weeks for the cannabis industry, with a few deals falling through the cracks and a couple execs leaving their companies. Aphria Inc (NYSE: APHA) tumbled Wednesday after rejecting Green Growth Brands Inc (OTC: GGBXF)'s hostile takeover bid. On the other hand, Argentina’s government authorized the country’s first medical cannabis grow operation, half owned by Aphria, in a move that bodes well for the company and other players with investments in Latin America.

  • ACCESSWIRE14 days ago

    4 Marijuana Stocks Looking To Pick Up Speed This Month

    CORAL GABLES, FL / ACCESSWIRE / February 8, 2019 / Marijuana stocks have become one of the hottest topics in the news over the course of the past few years. Recently, the cannabis industry has seen an increase in capital enjoyed by companies working to optimize and innovate products for the adult-use recreational cannabis market. As it relates to positive legislation brought forth by lawmakers, as many as 33 states in the U.S. have passed laws allowing for the use of cannabis, with many of those offering recreational cannabis as well.

  • 3 Brand-Name Marijuana Stocks Short-Sellers Are Liable to Target
    Motley Fool15 days ago

    3 Brand-Name Marijuana Stocks Short-Sellers Are Liable to Target

    These pot stocks are prime candidates to get smoked by pessimists.

  • GlobeNewswire15 days ago

    GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Period Ending 31 December 2018 and Host Conference Call on 26 February 2019

    GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 26 February, 2019 its financial results for the quarter ending 31 December, 2018. This is a transition period as GW will be moving to a new fiscal year-ending 31 December following this report on Form 10K-T. GW will also host a conference call the same day at 4:30 p.m. EST. A replay of the call will also be available through the Company's website ( shortly after the call.

  • InvestorPlace15 days ago

    Zynerba Stock Is Marijuana-Adjacent Play Worth a Look

    Lately, the pharmaceutical companies are trying to use cannabis-based therapies to treat all sorts of medical conditions. Zynerba (NASDAQ:ZYNE) is another contender in this increasingly-crowded field. Whether that's a good or bad thing for Zynerba stock remains to be seen.After all, they appear to have a pretty interesting play within the space. Their ZYN002 drug candidate is, according to the company, "the first and only pharmaceutically-produced CBD formulated as a permeation‑enhanced gel for transdermal delivery".They are running studies on this CBD gel for a variety of conditions. They are investigating treatments for Fragile X, Tourette's, and seizures, among other conditions.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Monster Growth Stocks to Buy for 2019 and Beyond Understanding The Fragile X Syndrome Therapeutic LandscapeFragile X Syndrome is a relatively rare condition occurring in roughly 1 out of every 4,000 boys and 1 out of every 8,000 girls. Researchers believe that the condition is caused by a DNA defect. Fragile X often presents symptoms in children by age 2 including intellectual disability and physical characteristics such as long face and a prominent jaw.It is sometimes a complicated diagnosis as Fragile X can look like other developmental disorders. Many Fragile X children have Attention Deficit Disorder. Additionally, many exhibit features of autism disorders. Furthermore, a significant number of Fragile X patients have frequent seizures.This leads to an interesting position for Zynerba. The company states that there are no approved drug therapies for Fragile X. However, it notes that doctors use various drugs off-label to treat various Fragile X symptoms. That makes sense, as there are treatments for things such as seizures.Directly, as far as competition, Zynerba notes that Neuren Pharmaceuticals, Ovid Therapeutics (NASDAQ:OVID) and Marinus Pharmaceuticals (NASDAQ:MRNS) are all active in the research space seeking a treatment directly for Fragile X syndrome.That's not all. Zynerba has focused on the treatment of seizures in particular. Within that particular space, it faces cannabinoid-based competition on several fronts. GW Pharma (NASDAQ:GWPH), with its more than $4 billion market cap, is targeting this space and is widely thought of as a leader in cannabinoid research.Additionally, Insys (NASDAQ:INSY) is researching CBDs for seizures and infantile spasms as well. So, should Zynerba's ZYN002 be a clinical success, it won't necessarily be the first or best therapy that reaches the market. Why Zynerba Stock Popped RecentlyOn January 28th, Zynerba stock shot up 30% to reach $4.80. In subsequent days, it rallied further, reaching as high as the $6 mark. What happened on Jan. 28 that set the rally in motion? There doesn't appear to be much in the way of hard news, but the company did give a high-profile presentation and it appears this set investor enthusiasm in motion.In this presentation, the company confirmed that things are moving along as planned for its combination Phase 2/3 CONNECT trail for Fragile X syndrome. Zynerba also expects to release results for its Phase 2 trial for developmental and epileptic encephalopathies in the latter half of 2019.To add to that, Zynerba remains in reasonably strong financial position. The company reported $59.8 million in cash as of December 31st, 2018.Given its current burn rate, that should give Zynerba funds to continue its current research through the second half of 2020. While Zynerba will have to raise more funds at some point, it still has plenty of time to deliver its crucial trial results later in 2019 before going back to the market for more money. The CBD FactorIt's difficult to consider ZYNE stock without thinking about the X factor here: investor enthusiasm for marijuana-related stocks. Since late December the Alternative Harvest (NYSEARCA:MJ) marijuana ETF has ripped 50% higher off the lows. Stocks like Aphria (NYSE:APHA) and Canopy Growth (NYSE:CGC) are soaring almost every day.Zynerba itself hadn't participated in this enthusiasm, at least not until recently. However, that may be changing. Recently, famous TV host Jim Cramer talked up so-called "marijuana-adjacent" biotech firms as stocks with big potential in 2019.Cramer said:"These are not pot companies. They are drug companies focused on developing artificial cannabinoids that mimic what cannabis does to your body […] As we get more and more data showing the efficacy of medicinal marijuana, I think more investors will embrace actual medicines that do the same thing as marijuana, but they do it more reliably."With ZYNE stock, you are getting a call option on this thesis playing out later in 2019. Zynerba Stock VerdictI rarely invest in clinical stage biotech companies. It's a difficult industry; far more companies fail than succeed. Be careful with these sorts of stocks and don't invest more than you can afford to lose.That said, Zynerba has an interesting drug candidate, and is certainly positioned in a hot sector of the market. With plenty of cash to make it into mid-2020, and key data coming before then, ZYNE stock has plenty of speculative value for active traders.One upcoming catalyst to watch out for. On February 11th, CEO Armando Anido will be giving a presentation at the 2019 BIO CEO and Investor Conference. With ZYNE stock remaining volatile in recent days, any further data releases or business updates in this presentation could cause a big move in Zynerba shares.At the time of this writing, Ian Bezek held no positions in any of the aforementioned securities. You can reach him on Twitter at @irbezek. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * Are These 7 Dividend Aristocrats ETFs Fit for a King? * 7 of the Best Emerging Markets Stocks to Buy * 5 Gold Stocks That Should Glitter in 2019 Compare Brokers The post Zynerba Stock Is Marijuana-Adjacent Play Worth a Look appeared first on InvestorPlace.